SULFASALAZINE 500mg. IP

A disease-modifying antirheumatic drug (DMARD) is used in the treatment and management of autoimmune conditions. (Choi & Fenando, 2021) Inhibits the formation of prostaglandins and reduces inflammation inside the body. The most effective agent for treating inflammatory bowel disease and rheumatoid arthritis. (C Wahl, 1998) Has been used worldwide for the treatment of inflammatory bowel diseases for over 40 years. (Dougados, 1993) A potential therapeutic option for various dermatological disorders due to antibacterial, anti-inflammatory, immunomodulation properties. (Sabha Mushtaq, 2020) Offers a more rapid onset of action than other DMARDs and slows down the radiological progression of rheumatoid arthritis. (C P Rains, 1995) Shown to have positive effects on rheumatic diseases such as rheumatoid arthritis and spondyloarthropathy. (Dougados M., 1993) Serves as an alternative option for patients with mild Crohn’s disease. (Choi & Fenando, 2021) An effective agent in inducing clinical improvement or remission in chronic inflammatory rheumatic diseases. (P Nurchis, 1990) A safe and useful therapeutic modality in patients with chronic reactive arthritis or ankylosing spondylitis. (S H Zwillich, 1988) Provides a statistically significant benefit in reducing the erythrocyte sedimentation rate and easing spinal stiffness in ankylosing spondylitis. (Junmin Chen, 2014)